Supernus Pharmaceuticals Net Worth
Supernus Pharmaceuticals Net Worth Breakdown | SUPN |
Supernus Pharmaceuticals Net Worth Analysis
Supernus Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Supernus Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Supernus Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Supernus Pharmaceuticals' net worth analysis. One common approach is to calculate Supernus Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Supernus Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Supernus Pharmaceuticals' net worth. This approach calculates the present value of Supernus Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Supernus Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Supernus Pharmaceuticals' net worth. This involves comparing Supernus Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Supernus Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Supernus Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Supernus Pharmaceuticals' net worth research are outlined below:
| Supernus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Supernus Pharmaceuticals currently holds 34.27 M in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Supernus Pharmaceuticals has a current ratio of 0.83, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Supernus Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| Over 95.0% of Supernus Pharmaceuticals shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Supernus Pharmaceuticals Upgraded at StockNews.com |
Supernus Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Supernus Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Supernus Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Supernus Pharmaceuticals Target Price Consensus
Supernus target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Supernus Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 5 | Strong Buy |
Most Supernus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Supernus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Supernus Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationSupernus Pharmaceuticals Target Price Projection
Supernus Pharmaceuticals' current and average target prices are 32.15 and 42.80, respectively. The current price of Supernus Pharmaceuticals is the price at which Supernus Pharmaceuticals is currently trading. On the other hand, Supernus Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Supernus Pharmaceuticals Market Quote on 23rd of March 2025
Target Price
Analyst Consensus On Supernus Pharmaceuticals Target Price
Know Supernus Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Supernus Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Supernus Pharmaceuticals backward and forwards among themselves. Supernus Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Supernus Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Loomis, Sayles & Company Lp | 2024-12-31 | 1.5 M | Gw&k Investment Management, Llc | 2024-12-31 | 1.2 M | American Century Companies Inc | 2024-12-31 | 1.1 M | Aristotle Capital Boston, Llc | 2024-12-31 | 1.1 M | Goldman Sachs Group Inc | 2024-12-31 | 934 K | Charles Schwab Investment Management Inc | 2024-12-31 | 753.4 K | Northern Trust Corp | 2024-12-31 | 717.2 K | Victory Capital Management Inc. | 2024-12-31 | 714.3 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 677.7 K | Blackrock Inc | 2024-12-31 | 10 M | Vanguard Group Inc | 2024-12-31 | 6.2 M |
Follow Supernus Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.79 B.Market Cap |
|
Project Supernus Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.10 | 0.11 | |
| Return On Capital Employed | 0.08 | 0.08 | |
| Return On Assets | 0.05 | 0.06 | |
| Return On Equity | 0.07 | 0.07 |
When accessing Supernus Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Supernus Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Supernus Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Supernus Pharmaceuticals' management efficiency
Supernus Pharmaceuticals has return on total asset (ROA) of 0.029 % which means that it generated a profit of $0.029 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0755 %, meaning that it created $0.0755 on every $100 dollars invested by stockholders. Supernus Pharmaceuticals' management efficiency ratios could be used to measure how well Supernus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Supernus Pharmaceuticals' Return On Tangible Assets are very stable compared to the past year. As of the 23rd of March 2025, Return On Capital Employed is likely to grow to 0.08, while Return On Equity is likely to drop 0.07. At this time, Supernus Pharmaceuticals' Intangibles To Total Assets are very stable compared to the past year. As of the 23rd of March 2025, Fixed Asset Turnover is likely to grow to 60.19, while Total Assets are likely to drop about 724.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 18.80 | 19.74 | |
| Tangible Book Value Per Share | 7.20 | 7.56 | |
| Enterprise Value Over EBITDA | 10.98 | 11.53 | |
| Price Book Value Ratio | 1.92 | 1.51 | |
| Enterprise Value Multiple | 10.98 | 11.53 | |
| Price Fair Value | 1.92 | 1.51 | |
| Enterprise Value | 2 B | 2.1 B |
Effective leadership at Supernus Pharmaceuticals drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Enterprise Value Revenue 2.0769 | Revenue | Quarterly Revenue Growth 0.06 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Supernus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Supernus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Supernus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Supernus Pharmaceuticals Corporate Filings
F4 | 11th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 25th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
| 5th of February 2025 Other Reports | ViewVerify |
Supernus Pharmaceuticals Earnings Estimation Breakdown
The calculation of Supernus Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Supernus Pharmaceuticals is estimated to be 0.38 with the future projection ranging from a low of 0.29 to a high of 0.46. Please be aware that this consensus of annual earnings estimates for Supernus Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.29 Lowest | Expected EPS | 0.46 Highest |
Supernus Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Supernus Pharmaceuticals' value are higher than the current market price of the Supernus Pharmaceuticals stock. In this case, investors may conclude that Supernus Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Supernus Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 5 | 53.37% | 0.5483 | 0.38 | 1.32 |
Supernus Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Supernus Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Supernus Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Supernus Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Supernus Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Supernus Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Supernus Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Supernus Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Supernus Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-25 | 2024-12-31 | 0.52 | 0.5483 | 0.0283 | 5 | ||
2024-11-04 | 2024-09-30 | 0.44 | 0.69 | 0.25 | 56 | ||
2024-08-06 | 2024-06-30 | 0.31 | 0.36 | 0.05 | 16 | ||
2024-05-08 | 2024-03-31 | 0.38 | 0.26 | -0.12 | 31 | ||
2024-02-27 | 2023-12-31 | 0.55 | 0.89 | 0.34 | 61 | ||
2023-11-08 | 2023-09-30 | 0.08 | 0.24 | 0.16 | 200 | ||
2023-08-08 | 2023-06-30 | -0.23 | -0.02 | 0.21 | 91 | ||
2023-05-09 | 2023-03-31 | 0.17 | 0.29 | 0.12 | 70 | ||
2023-02-28 | 2022-12-31 | 0.68 | 0.43 | -0.25 | 36 | ||
2022-11-08 | 2022-09-30 | 0.36 | 0.03 | -0.33 | 91 | ||
2022-08-04 | 2022-06-30 | 0.29 | 0.14 | -0.15 | 51 | ||
2022-05-09 | 2022-03-31 | 0.24 | 0.43 | 0.19 | 79 | ||
2022-02-28 | 2021-12-31 | 0.24 | 0.04 | -0.2 | 83 | ||
2021-11-03 | 2021-09-30 | 0.23 | 0.4 | 0.17 | 73 | ||
2021-08-04 | 2021-06-30 | 0.2 | 0.43 | 0.23 | 115 | ||
2021-05-05 | 2021-03-31 | 0.24 | 0.11 | -0.13 | 54 | ||
2021-02-25 | 2020-12-31 | 0.52 | 0.57 | 0.05 | 9 | ||
2020-11-03 | 2020-09-30 | 0.3 | 0.74 | 0.44 | 146 | ||
2020-08-17 | 2020-06-30 | 0.42 | 0.65 | 0.23 | 54 | ||
2020-05-05 | 2020-03-31 | 0.28 | 0.4 | 0.12 | 42 | ||
2020-02-25 | 2019-12-31 | 0.6 | 0.62 | 0.02 | 3 | ||
2019-11-05 | 2019-09-30 | 0.6 | 0.54 | -0.06 | 10 | ||
2019-08-06 | 2019-06-30 | 0.58 | 0.61 | 0.03 | 5 | ||
2019-05-07 | 2019-03-31 | 0.47 | 0.34 | -0.13 | 27 | ||
2019-02-26 | 2018-12-31 | 0.27 | 0.48 | 0.21 | 77 | ||
2018-11-06 | 2018-09-30 | 0.41 | 0.52 | 0.11 | 26 | ||
2018-08-07 | 2018-06-30 | 0.43 | 0.57 | 0.14 | 32 | ||
2018-05-08 | 2018-03-31 | 0.33 | 0.49 | 0.16 | 48 | ||
2018-02-27 | 2017-12-31 | 0.27 | 0.44 | 0.17 | 62 | ||
2017-11-06 | 2017-09-30 | 0.27 | 0.29 | 0.02 | 7 | ||
2017-08-02 | 2017-06-30 | 0.24 | 0.32 | 0.08 | 33 | ||
2017-05-09 | 2017-03-31 | 0.22 | 0.19 | -0.03 | 13 | ||
2017-01-20 | 2016-12-31 | 0.34 | 0.37 | 0.03 | 8 | ||
2016-12-13 | 2016-09-30 | 0.34 | 0.37 | 0.03 | 8 | ||
2016-08-02 | 2016-06-30 | 0.13 | 0.18 | 0.05 | 38 | ||
2016-05-03 | 2016-03-31 | 0.09 | 0.08 | -0.01 | 11 | ||
2016-03-02 | 2015-12-31 | 0.06 | 0.14 | 0.08 | 133 | ||
2015-11-03 | 2015-09-30 | 0.02 | 0.08 | 0.06 | 300 | ||
2015-08-04 | 2015-06-30 | 0.02 | 0.03 | 0.01 | 50 | ||
2015-05-05 | 2015-03-31 | -0.01 | 0.02 | 0.03 | 300 | ||
2015-03-10 | 2014-12-31 | -0.12 | 0.1 | 0.22 | 183 | ||
2014-11-11 | 2014-09-30 | 0.36 | 0.39 | 0.03 | 8 | ||
2014-08-11 | 2014-06-30 | -0.15 | 0.08 | 0.23 | 153 | ||
2014-05-12 | 2014-03-31 | -0.41 | -0.35 | 0.06 | 14 | ||
2014-03-12 | 2013-12-31 | -0.55 | -0.39 | 0.16 | 29 | ||
2013-11-12 | 2013-09-30 | -0.67 | -0.64 | 0.03 | 4 | ||
2013-08-13 | 2013-06-30 | -0.65 | -0.57 | 0.08 | 12 | ||
2013-05-13 | 2013-03-31 | -0.71 | -0.6 | 0.11 | 15 | ||
2013-03-14 | 2012-12-31 | -0.71 | -0.51 | 0.2 | 28 | ||
2012-11-07 | 2012-09-30 | -0.62 | -0.55 | 0.07 | 11 | ||
2012-08-10 | 2012-06-30 | -0.48 | -0.61 | -0.13 | 27 |
Supernus Pharmaceuticals Corporate Management
| Padmanabh Bhatt | Chief Scientific Officer and Sr. VP of Intellectual Property | Profile | |
| Tami Martin | VP Affairs | Profile | |
| Jeff Bozick | Senior Chain | Profile | |
| Kevin Esq | Compliance Officer | Profile | |
| Taylor Raiford | Senior Sales | Profile | |
| Bryan Roecklein | Senior Development | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 14.447 | Earnings Share 1.32 | Revenue Per Share | Quarterly Revenue Growth 0.06 | Return On Assets |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.